Silence Therapeutics DEF 14A: Executive Compensation Details
Ticker: SLNCF · Form: DEF 14A · Filed: May 16, 2025 · CIK: 1479615
| Field | Detail |
|---|---|
| Company | Silence Therapeutics PLC (SLNCF) |
| Form Type | DEF 14A |
| Filed Date | May 16, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, executive-compensation, equity-awards
TL;DR
Silence Therapeutics DEF 14A out - exec comp details for FY24, including equity awards for Tooman & Rothera.
AI Summary
Silence Therapeutics plc filed a DEF 14A on May 16, 2025, for the period ending June 26, 2025. The filing details executive compensation and related matters for the fiscal year ending December 31, 2024. Key information includes equity awards granted to individuals like Mr. Tooman and Mark Rothera.
Why It Matters
This filing provides transparency into how Silence Therapeutics compensates its top executives, which can influence investor perception and company strategy.
Risk Assessment
Risk Level: low — This is a routine filing detailing executive compensation and does not indicate immediate financial risk.
Key Numbers
- 2024-12-31 — Fiscal Year End (Reporting period for executive compensation details.)
- 2025-06-26 — Period of Report (The period this DEF 14A filing pertains to.)
Key Players & Entities
- Silence Therapeutics plc (company) — Filer
- Mr. Tooman (person) — Executive
- Mark Rothera (person) — Executive
- 0001193125-25-121232 (dollar_amount) — Accession Number
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Definitive Proxy Statement, is filed by companies to solicit shareholder votes and provides detailed information about matters to be voted on at an annual or special meeting, including executive compensation.
Who are the key individuals mentioned in relation to equity awards?
The filing mentions equity awards granted to Mr. Tooman and Mark Rothera.
What is the filing date of this DEF 14A?
The filing date is May 16, 2025.
What is the standard industrial classification for Silence Therapeutics plc?
The Standard Industrial Classification for Silence Therapeutics plc is Pharmaceutical Preparations [2834].
What is the business address of Silence Therapeutics plc?
The business address is 72 Hammersmith Road, London, W14 8TH.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on May 16, 2025 by Mr. Tooman regarding Silence Therapeutics plc (SLNCF).